冷凝集素病市场：现况分析及预测（2023-2030）

由于针对冷凝集素疾病的潜在治疗方法的研究和开发不断增加，预计冷凝集素疾病市场在预测期内将以 18% 的复合年增长率强劲增长。例如，Enjaymo 于 2022 年 2 月获得 FDA 的美国上市批准，以减少患有中枢神经系统慢性阻塞性疾病的成年人对红血球输注的需求。该药物是 FDA 批准的第一个也是唯一一个用于治疗冷凝集素病患者的药物。它的作用是抑制红血球的破坏。其他几个因素，例如临床试验数量的增加、研究投资和患者治疗结果的改善，也导致了市场的激增。例如，2022年2月，Sanofi进行了1b期临床试验，以评估Bioverativ（BIVV020）在冷凝集素疾病患者中的安全性、耐受性和药物动力学。

依药物划分，市场分为皮质类固醇、烷化剂、嘌呤核甘类似物、生物製剂等。由于技术进步和人们对该疾病的认识不断提高，皮质类固醇细分市场在 2022 年占据了最高的市场份额。其他因素，例如老年人口的增加，也加强了皮质类固醇在冷凝集素疾病市场中的地位，因为老一代更容易患这种疾病。例如，世界卫生组织（WHO）在2022年10月报告称，2015年至2050年间，全球60岁及以上人口将几乎翻倍，从12%增至22%，冷凝集素疾病市场将增加。以稳定的速度推进。因此，皮质类固醇将在2022年占据很大的市场。

根据给药途径，市场分为口服、肠胃外和其他。由于消费便利性、对冷凝集素病等慢性病的认识不断提高、对微创治疗的需求不断增加以及医疗保健专业人员对此类治疗程序的接受程度不断提高，预计口服药物细分市场将在预测期内部增长。复合年增长率最高。例如，根据 Frontiers 2021 年 2 月的一篇文章“口服药物递送的进展”，最广泛使用的药物递送方法是口服途径，市场上大约 60% 的小分子药物都是通过这种方式递送的。 。因此，预计在预测期内，口腔细分市场将在市场上占据主导地位。

根据最终用户，市场分为医院、专科诊所等。医院类别根据医院提供的医疗服务的可及性、高素质医疗人员的可用性、先进医疗技术的利用以及世界各地的单位数量的多样化而按医院分类。2022 年。例如，根据美国医院协会2023年的数据，2022年美国共有6,129家医院，拥有病床诊所919,649个，住院病人数为34,011,386人。医院领域的市场竞争非常激烈，预计这种情况在可预见的未来仍将持续。因此，2022年的市场规模将由医院产业主导。

为了更了解冷凝集素病产业的市场实施情况，市场已细分为北美（美国、加拿大和北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利和欧洲其他地区），亚太地区（中国、日本、印度、亚太地区其他地区）以及中东和非洲的世界其他地区。预计亚太地区在预测期内将以最高的复合年增长率成长。这是由于市场上存在着大公司、冷凝集素疾病日益流行以及完善的学术和研究机构的存在。例如，2021 年 9 月，Aleph Pharmaceuticals, Inc. 宣布在日本推出 Ultomiris，用于治疗冷凝集素疾病。印度和中国等国家为临床研究提供了有吸引力的投资机会，预计将积极推动冷凝集素疾病的研发。因此，由于亚太地区人口规模庞大，预计在预测期内将以高复合年增长率成长。

目录

第一章 市场介绍

• 市场定义
• 主要目标
• 利益相关者
• 限制

第二章 研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章主要市场洞察

第 4 章执行摘要

第五章 新模式对冷凝集素病市场的影响

第六章冷凝集素疾病市场收入，2020-2030

第七章 药品市场洞察

• 皮质类固醇
• 烷基化剂
• 嘌呤核甘类似物
• 生物製品
• 其他

第 8 章依给药途径划分的市场洞察

• 口服
• 肠外
• 其他

第 9 章 最终用户的市场洞察

• 医院
• 专科诊所
• 其他

第 10 章 按应用划分的市场洞察

• 家用
• 非住宅

第十一章按地区划分的市场洞察

• 北美
  • 美国
  • 加拿大
  • 北美其他地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 亚太其他地区
• 世界其他地区 中东/非洲

第十二章冷凝集素病市场动态

• 市场驱动力
• 市场挑战
• 影响分析

第十三章冷凝集素疾病市场机会

第十四章冷凝集素病市场趋势

第十五章需求侧与供给面分析

• 需求面分析
• 供给侧分析

第十六章价值链分析

第17章价格分析

第十八章战略洞察

第19章 竞争场景

• 竞争格局
• 波特五力分析

第二十章 公司简介

• Heil
• McNeilus Truck and Manufacturing
• Labrie Group
• Curbtender Sweepers, LLC
• Geesink
• Bridgeport Manufacturing
• FAUN Umwelttechnik GmbH & Co. KG
• Haul-All Equipment Ltd.
• Fratelli Mazzocchia Spa
• Nord Engineering s.p.a

第21章 免责声明

Cold agglutinin disease (CAD) is a rare autoimmune disorder that can cause the human body to produce antibodies that attack and destroy red blood cells, leading to anemia and other symptoms. It is associated with clonal B-cell lymphoproliferative cells (AIHA). It can be caused by a variety of factors, including genetics, infections, and certain medications. Some common symptoms of CAD include fatigue, weakness, pale skin, shortness of breath, and fever. Symptoms of CAD tend to be exacerbated during cold weather. The cold agglutinin disease market is growing at a tremendous rate owing to a surge in the number of disease cases, increased focus on early detection and prevention, advances in treatment options, and a rise in the geriatric population. For instance, according to the American Society of Hematology in December 2021, the estimated incidence rate of cold agglutinin disease is between 5 and 20 per million individuals and between 0.5 and 1.9 per million individuals per year.

The Cold Agglutinin Disease Market is expected to grow at a strong CAGR of 18% during the forecast period owing to the rising research and developments for finding a potential cure for cold agglutinin disease. For instance, Enjaymo was granted marketing authorization in the U.S. by the FDA in February 2022, with the purpose of reducing the requirement for red blood cell transfusions in adults with chronic obstructive diseases of the central nervous system. This is the first and only FDA-approved treatment for people with cold agglutinin disease. It works by blocking the destruction of red blood cells. Several other factors such as increased number of clinical trials, investment in research, and improved patient outcomes are also leading to the surge in the market. For instance, in February 2022, a Phase 1b clinical study was conducted by Sanofi to evaluate the safety, tolerability, and pharmacokinetics of Bioverativ (BIVV020) in patients with cold agglutin diseases.

Based on drugs, the market is segmented into corticosteroids, alkylating agents, purine nucleoside analogs, biologics, and others. The corticosteroids segment held the highest share in the market in the year 2022 owing to technological progress, and increased awareness of the condition. Other factors such as the rise in the geriatric population are also strengthening grounds for the corticosteroids segment in the cold agglutinin disease market as the older generation is more prone to getting affected by the disease. For instance, the World Health Organization (WHO) reported in October 2022 that between 2015 to 2050, the segment of the world's population over 60 years will nearly double from 12% to 22%, which will propel the cold agglutinin disease market at a steady rate. Hence, the corticosteroids segment held a significant share of the market in the year 2022.

Based on the route of administration, the market is bifurcated into oral, parenteral, and others. The oral segment is expected to grow with the highest CAGR during the forecast period owing to the ease of consumption, growing awareness of chronic conditions like cold agglutinin disease, the increased need for minimally invasive treatments, and the growing acceptance of such treatment procedures by healthcare professionals. For instance, according to Frontiers article, Advances in Oral Drug Delivery in February 2021, the most widely used method of drug administration is through the oral route, with approximately 60% of commercially available small molecule drug products being administered this way. Thus, the oral segment is expected to gain prominence in the market in the forecast period.

Based on end-users, the market is segmented into hospitals, specialty clinics, and others. The hospitals category held the highest share in the market in 2022 attributed to the ease of access to healthcare provided by hospitals, the availability of highly qualified healthcare personnel, the utilization of advanced medical technology, and a diverse number of units all over the globe. For instance, according to the American Hospital Association in 2023, there are in total of 6,129 hospitals in the U.S with 919,649 staffed beds and 34,011,386 hospital admissions in the year 2022. The market for the hospital segment is highly competitive and is projected to remain so in the foreseeable future. Thus, the hospital segment held dominance in the market in the year 2022.

For a better understanding of the market adoption of the cold agglutinin disease industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with the highest CAGR during the forecast period. This is due to the presence of major players in the market, the increasing incidence of cold agglutinin disorder, and the presence of well-established academic and research institutes. For example, in September 2021, Aleph Pharmaceuticals, Inc., announced that it would launch Ultomiris in Japan for the treatment of cold agglutinin disorder. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for cold agglutinin disease. Hence, given the large population size of APAC, it is expected to grow with a high CAGR during the forecast period.

Some of the major players operating in the market include: Johnson & Johnson Services, Inc., Novartis AG; Bayer AG; Pfizer Inc.; Sanofi; AstraZeneca; Bristol-Myers Squibb Company; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; GSK plc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Waste or Garbage Collection Vehicle Market
• 2.2. Research Methodology of the Waste or Garbage Collection Vehicle Market
• 2.3. Respondent Profile

3 MARKET KEY INSIGHTS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE WASTE OR GARBAGE COLLECTION VEHICLE MARKET

6 WASTE OR GARBAGE COLLECTION VEHICLE MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY LOADER TYPE

• 7.1. Front Loader
• 7.2. Rear Loader
• 7.3. Automated Side Loader
• 7.4. Others

8 MARKET INSIGHTS BY VEHICLE TYPE

• 8.1. Light Duty
• 8.2. Medium Duty
• 8.3. Heavy Duty

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. Manual
• 9.2. Semi-Automatic

10 MARKET INSIGHTS BY APPLICATION

• 10.1. Residential
• 10.2. Non-Residential

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. The U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. The U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. India
  • 11.3.3. Japan
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 WASTE OR GARBAGE COLLECTION VEHICLE MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 WASTE OR GARBAGE COLLECTION VEHICLE MARKET OPPORTUNITIES

14 WASTE OR GARBAGE COLLECTION VEHICLE MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 PRICING ANALYSIS

18 STRATEGIC INSIGHTS

19 COMPETITIVE SCENARIO

• 19.1. Competitive Landscape
• 19.2. Porters Fiver Forces Analysis

20 COMPANY PROFILED

• 20.1. Heil
• 20.2. McNeilus Truck and Manufacturing
• 20.3. Labrie Group
• 20.4. Curbtender Sweepers, LLC
• 20.5. Geesink
• 20.6. Bridgeport Manufacturing
• 20.7. FAUN Umwelttechnik GmbH & Co. KG
• 20.8. Haul-All Equipment Ltd.
• 20.9. Fratelli Mazzocchia Spa
• 20.10. Nord Engineering s.p.a

21 DISCLAIMER